Bastiano Sanna - Feb 1, 2022 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, Cell & Genetic Therapies
Signature
/s/ Sabrina Yohai, Attorney-in-Fact
Stock symbol
VRTX
Transactions as of
Feb 1, 2022
Transactions value $
-$389,172
Form type
4
Date filed
2/3/2022, 03:26 PM
Previous filing
Nov 3, 2021
Next filing
Feb 14, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Award $0 +11.6K +35.69% $0.00 44.2K Feb 1, 2022 Direct F1
transaction VRTX Common Stock Award $0 +12.3K +27.86% $0.00 56.5K Feb 1, 2022 Direct F2
transaction VRTX Common Stock Tax liability -$128K -526 -0.93% $243.64 56K Feb 1, 2022 Direct
transaction VRTX Common Stock Sale -$168K -670 -1.2% $250.04 55.3K Feb 2, 2022 Direct F3, F4, F5
transaction VRTX Common Stock Sale -$35.5K -141 -0.25% $251.47 55.2K Feb 2, 2022 Direct F3, F5, F6
transaction VRTX Common Stock Sale -$37.7K -149 -0.27% $253.07 55K Feb 2, 2022 Direct F3, F5, F7
transaction VRTX Common Stock Sale -$16.3K -64 -0.12% $253.95 55K Feb 2, 2022 Direct F3, F5, F8
transaction VRTX Common Stock Sale -$4.07K -16 -0.03% $254.54 55K Feb 2, 2022 Direct F3, F5, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest in installments beginning on 02/17/2022.
F2 Restricted stock unit award that vests in installments beginning on 02/24/2023.
F3 Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1.
F4 Open market sales reported on this line occurred at a weighted average price of $250.04 (range $250.00 to $250.97).
F5 Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F6 Open market sales reported on this line occurred at a weighted average price of $251.47 (range $251.09 to $251.85).
F7 Open market sales reported on this line occurred at a weighted average price of $253.07 (range $252.44 to $253.42).
F8 Open market sales reported on this line occurred at a weighted average price of $253.95 (range $253.47 to $254.42).
F9 Open market sales reported on this line occurred at a weighted average price of $254.54 (range $254.47 to $254.80).

Remarks:

Exhibit 24 - Power of Attorney